News | April 29, 2023
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
The Theme of the event was 'Building One Health Together – Improving Health Equity'
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Affordability is key to providing accessible healthcare for Bharat.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Subscribe To Our Newsletter & Stay Updated
